Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS c.*2626T>G
(
ENST00000256078.10,
ENST00000688940.1,
ENST00000553788.6,
ENST00000692768.1,
ENST00000685328.1,
ENST00000693229.1,
ENST00000311936.8 )
KRAS c.*2626T>G ( ENST00000256078.10, ENST00000311936.8, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1, ENST00000553788.6 ) - Associated Disease
- ovary epithelial cancer
- Source Database
- CIViC Evidence
- Description
- The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EOC patients without BRCA mutations were used in this study. Furthermore, the researchers tested a KRAS-variant EOC cell line (BG1) and found it has much greater platinum-based chemotherapy resistance than a non-KRAS-variant cell line (CAOV3).
- Variant Origin
- Common Germline
- Variant Origin
- Common Germline
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/664
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/254
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Epithelial Ovarian Cancer
- Evidence Direction
- Supports
- Drug
- Carboplatin,Paclitaxel
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 22139083
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Carboplatin | Resitance or Non-Reponse | true |
| Paclitaxel | Resitance or Non-Reponse | true |